Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/150494
Authors: 
Gros, Blanca
Galán, Antonio
González-Parra, Emilio
Herrero, Jose A.
Echave, Maria
Vegter, Stefan
Tolley, Keith
Oyagüez, Itziar
Year of Publication: 
2015
Citation: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 5 [Year:] 2015 [Issue:] 14 [Pages:] 1-9
Abstract: 
AIMS: In Spain, the first line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) consists of calciumbased phosphate binders (CB). However, their use is associated with vascular calcification and an increased mortality risk. The aim of this study was to assess the incremental cost-effectiveness of second-line Lanthanum Carbonate (LC) treatment in patients not responding to CB (calcium carbonate and calcium acetate). Material and methods: A lifetime Markov model was developed considering three health states (predialysis, dialysis and death). Transitions between states and efficacy data were obtained from randomized clinical trials and the European Dialysis and Transplant Association Annual report. Mortality rate was adjusted with the relative risk related to serum phosphorus levels. According to the Spanish healthcare system perspective, only medical direct costs were considered. Dialysis costs (2013 prices in Euros) were obtained from diagnosis-related groups. Drug costs were derived from ex-factory prices, adjusted with 7.5% mandatory rebate. Quality of life estimates were based on a published systematic review. Costs and benefits were discounted at 3%. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. Results: At the end of simulation, costs per patient with LC therapy were €1,169 and €5,044 with CB alone. 4.653 Quality Adjusted Life Years (QALYs) were gained per patient treated with LC, and 4.579 QALYs with CB. CB therapy is dominated by the LC strategy (i.e. lower costs, higher QALYs). Assuming a €30,000/QALY threshold, LC was dominant in 100% of PSA simulations. Conclusions: LC is a cost-effective second line treatment of hyperphosphatemia in CKD patients irrespective of dialysis status in Spain.
Subjects: 
Hyperphosphatemia
Calcium binders
Lanthanum carbonate
Predialysis
Dialysis
Persistent Identifier of the first edition: 
Creative Commons License: 
http://creativecommons.org/licenses/by/4.0/
Document Type: 
Article

Files in This Item:
File
Size
705.55 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.